Transcranial Magnetic Stimulation in Australia has emerged as one of the most promising therapies for people living with major depressive disorder (MDD), especially when traditional antidepressants fail. Using targeted electromagnetic pulses, TMS can modulate brain activity in specific regions associated with mood regulation, often leading to significant symptom improvement with minimal side effects.
Despite its effectiveness and approval by Australia’s Therapeutic Goods Administration (TGA) for treatment resistant depression (TRD) since 2007, TMS remains primarily available through private clinics, leaving public mental health patients with limited access.
A Growing Need for New Depression Treatments
Major depressive disorder affects roughly 280 million people globally, with about 20 percent of individuals experiencing it at some point in their lives. In Australia, depression not only disrupts personal well being but also imposes economic costs through reduced productivity and increased healthcare use. Alarmingly, around half of those with MDD meet the criteria for treatment resistant depression, meaning they do not respond to at least two standard antidepressant medications.
For this group, TMS provides a powerful alternative. Clinical studies show that 58–83 percent of patients respond positively, and up to 62 percent achieve remission after TMS therapy. Unlike electroconvulsive therapy (ECT), TMS does not require anesthesia, does not cause memory loss, and is generally well tolerated.
Why Transcranial Magnetic Stimulation Should Be More Accessible
Although TMS devices require specialized equipment and trained technicians, multiple cost analyses have shown that the therapy is economically viable in the long run. Patients receiving TMS tend to have fewer hospital admissions and emergency visits compared to those relying on medication alone. Over time, this translates to substantial savings for healthcare systems.
The limited adoption of TMS in Australia’s public sector appears to stem partly from lack of familiarity among senior clinicians and misconceptions about cost effectiveness. Currently, TMS is available in private facilities across major cities like Sydney, Melbourne, and Brisbane, and in some regional centers. However, public hospitals, such as Hornsby, Royal North Shore, and Nepean offer few or no TMS programs.
This imbalance means that many Australians with severe depression must either pay out of pocket or go without care, creating inequities in treatment access.
How TMS Works to Restore Brain Function
TMS operates on the principles of electromagnetic induction. The therapy uses a coil placed near the scalp to generate magnetic fields that stimulate electrical activity in the brain’s cortical regions. These signals promote communication between neural networks and enhance the expression of genes involved in neuroplasticity, including SCN1A and SNAP25.
By strengthening brain circuits responsible for emotional regulation, TMS can restore balance in the neural pathways disrupted by depression and other psychiatric disorders.
Newer techniques, such as theta-burst stimulation, have made TMS sessions faster and more efficient, producing similar therapeutic outcomes in a fraction of the time.
Building the Future of Public TMS Access
For TMS to become a standard option in public health care, investment in clinician training and equipment acquisition is essential. The process is not complicated, psychiatrists and mental health professionals can be trained within hours to operate TMS systems safely.
Making this treatment available to patients who rely on public hospitals would represent a major step forward for mental health equity in Australia. As the global evidence base continues to expand, it is increasingly clear that TMS is not just an advanced technology. It is a life changing therapy that deserves broader public adoption.
References
- Lefaucheur JP, et al. “Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS).” Clinical Neurophysiology, 2020. https://doi.org/10.1016/j.clinph.2020.02.003
- Zemplényi A, Józwiak-Hagymásy J, Kovács S, et al. Repetitive transcranial magnetic stimulation may be a cost-effective alternative to antidepressant therapy after two treatment failures in patients with major depressive disorder. BMC Psychiatry. 2022;22:437.https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-022-04078-9?